top of page
Insights for Life Sciences Talent Leaders
Strategic guidance on life sciences executive recruitment and human capital for search partners, biotech innovators, and scale-up HR leaders. I also share occasional personal reflections on the industry.


GLP-1s Beyond Obesity: What the Evidence Really Shows
GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology.
Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders:
In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and
sharonshieldsconsu
Sep 283 min read


Redefining Neurodegeneration: From Plaques and Pathology to Systemic Network Dysfunction
From Single Targets to Systems Biology: A New Framework for Neurodegenerative R&D
For three decades, neurodegeneration programmes have been built around a tightly focused premise: find the toxic protein, clear it from the brain, protect the vulnerable neuron. Alzheimer’s was framed as an amyloid and tau problem. Parkinson’s as a dopamine and alpha-synuclein problem. ALS as a motor neuron problem.
That framing has driven real progress – from disease-modifying antibodies to g
sharonshieldsconsu
Sep 75 min read


Tilting the Scales: GLP‑1 Drugs, Obesity, and Who Gets to Rewrite Their Biology
GLP‑1 weight‑loss drugs started as diabetes medicines. Now they’re quietly becoming one of the most powerful tools in obesity treatment — and they’re still evolving.
The science is advancing quickly. The harder question is whether access, cost, and policy will keep up.
sharonshieldsconsu
Aug 23 min read


The Growing Momentum Behind Neurodegenerative Disease Research
How innovation, investment and talent are advancing Alzheimer's disease and other neurological disorders Intricate digital rendering of a brain, with a network-like structure against a dark background, highlighting the complexity of neural connections. My interest in neuroscience and neurodegenerative diseases stems from both professional and personal experience. My first step into executive search was through a Talent Acquisition role at a pharmaceutical neuroscience researc
sharonshieldsconsu
Jul 34 min read
bottom of page